PDX-Derived Head and Neck Cancer Organoid Model

Head and neck cancer is the sixth most common tumor, with head and neck squamous cell carcinomas (HNSCCs) accounts for about 90% in various disease subtypes. Different from other cancers, its treatment has not been fully developed over the decades. This is mainly because of the high heterogeneity of this disease. At Creative Biolabs, we have built a professional team to develop new 3D models such as PDX-derived head and neck cancer organoids to serve our global customers.

Shortcomings of Common Models

During the past decades, HNSCC cell lines offer an affordable tool to study the molecular biology of tumors so as to perform novel drug screening. However, their effects are limited for predicting the in vivo behavior of tumors and are inapplicable to designing a personalized treatment plan for patients. Meanwhile, genetically modified mice (GMM) are effective for genetic mechanism research, but also have some shortcomings, such as low tumor penetrance and uncertain results. Another famous mouse model, patient-derived xenograft (PDX) model, creates a convenient condition for displaying metastasis and local bone invasion, but is challenging to generate the model in immunocompetent recipients.

Advantages of PDX-derived Head and Neck Cancer Organoid Models

The 3D organoid technology has expanded to the head and neck cancer field after many attempts. To date, several researchers have foreseen the advantages of PDX-derived HNSCC organoid, which including but not limited to:

• Show the in vivo architecture and cellular environment of the original tumors and provide more indicative information for biomarker generation.
• Preserve the proliferation capability and high heterogeneity in the tumor microenvironment (TME).
• More effectively recapitulate the tumor morphology and gene expression activity, and predict drug therapy responses in the human body.
• Involve fewer ethical issues, a shorter modeling time and present a faster growth rate in vitro environment, as opposed to PDX models.

Potential Applications

The birth of microfluidic technology brings a new opportunity for the rapid development of PDX-derived organoids. In the future, it’s hopeful that PDX-derived head and neck cancer organoid models will play an essential role in basic drug research and clinical therapy development.

Fig.1 Potential applications of PDX-derived head and neck cancer organoids. (Creative Biolabs)

Related Services

Creative Biolabs is a reputable biotech company that is committed to developing novel 3D modeling technology. Over the decades, we devoted ourselves to the 3D biology field and have built a variety of ex vivo physiological models including 3D organoid models. As long as you have a need, we are ready to offer the first-rate PDX-derived head and neck cancer organoid model and related drug discovery and development services listed below to enhance the progress of your preclinical drug research with greater efficiency. For mode details, please feel free to contact us.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model